GSK and Pfizer have launched their HIV focused JV, ViiV Healthcare with the promise that it will undertake “relentless pursuit” of new drugs.
The joint venture (JV), which was formed by GlaxoSmithKline (GSK) and Pfizer in April, has rights to a portfolio of 10 HIV treatments, including Epzicom and Selzentry which generated combined revenues of £1.6bn (€1.8bn) in 2008.
ViiV also has seven candidate HIV treatments in development, five opf which are being examined in Phase II trials.
Dominique Limet, CEO of the new firm, explained that: “[ViiV’s] R&D efforts, strategic partnerships and licensing opportunities will be focussed on delivering medications that help address resistance issues and dosing complexity."
Dr Limet stressed that the firm’s R&D efforts “will not solely focus on creating ‘new’ medicines,” adding that it will explore the broader potential of all of the molecules in its portfolio.